摘要:
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature to predict response to niraparib. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature to predict response to niraparib are provided.
摘要:
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
摘要:
Biomarkers and methods using the biomarkers for molecular detection and classification of disease and, particularly, molecular markers for cancer diagnosis and prognosis and methods of use thereof are provided.
摘要:
The invention provides for molecular classification of disease and, particularly, molecular markers for lung cancer prognosis and therapy selection and methods and systems of use thereof.
摘要:
The disclosure provides for molecular classification of disease and, particularly, molecular markers for breast cancer prognosis and methods and systems of use thereof.